These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35240926)

  • 1. Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study.
    Debellut F; Pecenka C; Hausdorff WP; Clark A
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040329. PubMed ID: 35240926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.
    Mooney J; Price J; Bain C; Bawa JT; Gurley N; Kumar A; Liyanage G; Mkisi RE; Odero C; Seck K; Simpson E; Hausdorff WP
    PLoS One; 2022; 17(6):e0270369. PubMed ID: 35737718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.
    Price J; Mooney J; Bain C; Bawa JT; Gurley N; Kumar A; Liyanage G; Mkisi RE; Odero C; Seck K; Simpson E; Hausdorff WP
    Vaccine; 2022 Jan; 40(2):370-379. PubMed ID: 34863614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines.
    Hausdorff WP; Price J; Debellut F; Mooney J; Torkelson AA; Giorgadze K; Pecenka C
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of rotavirus vaccination in Mozambique.
    Lourenço Guimarães E; Chissaque A; Pecenka C; Clark A; Vaz B; Banze A; Canana N; Romão C; do Rosário Oliveira Martins M; de Deus N; Debellut F
    Vaccine; 2022 Aug; 40(36):5338-5346. PubMed ID: 35933279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
    Patel HD; Roberts ET; Constenla DO
    Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
    Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
    Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Tucker AW; Haddix AC; Bresee JS; Holman RC; Parashar UD; Glass RI
    JAMA; 1998 May; 279(17):1371-6. PubMed ID: 9582045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
    Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
    Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation rotavirus vaccine developers meeting: Summary of a meeting sponsored by PATH and the bill & melinda gates foundation (19-20 June 2019, Geneva).
    Fix A; Kirkwood CD; Steele D; Flores J
    Vaccine; 2020 Dec; 38(52):8247-8254. PubMed ID: 33234304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.
    Bruijning-Verhagen P; van Dongen JAP; Verberk JDM; Pijnacker R; van Gaalen RD; Klinkenberg D; de Melker HE; Mangen MJ
    BMC Med; 2018 Sep; 16(1):168. PubMed ID: 30196794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
    Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.